c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Products of "c-Met/HGFR"
Sort by
Canlitinib
CAS:Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.Formula:C33H31F2N3O7Purity:98%Color and Shape:SolidMolecular weight:619.61SRI 31215 TFA
CAS:SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Formula:C27H34F3N5O3Purity:98.25% - 99.97%Color and Shape:SolidMolecular weight:533.6Ref: TM-T5478
1mg43.00€5mg96.00€10mg135.00€25mg261.00€50mg391.00€100mg557.00€200mg753.00€1mL*10mM (DMSO)101.00€1D228
1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration ofPurity:98%Color and Shape:Odour SolidCEP-40783
CAS:CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).Formula:C31H26F2N4O6Purity:99.45% - 99.64%Color and Shape:SolidMolecular weight:588.56Merestinib
CAS:Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Formula:C30H22F2N6O3Purity:95% - 99.56%Color and Shape:SolidMolecular weight:552.53Ref: TM-T3455
1mg49.00€2mg70.00€5mg105.00€10mg144.00€25mg254.00€50mg424.00€100mg605.00€500mg1,264.00€1mL*10mM (DMSO)126.00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Formula:C19H16N8OPurity:98.41% - 98.55%Color and Shape:SolidMolecular weight:372.38Ref: TM-T2676
1mg38.00€2mg49.00€5mg73.00€10mg97.00€25mg172.00€50mg288.00€100mg520.00€1mL*10mM (DMSO)79.00€Afatinib
CAS:Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.Formula:C24H25ClFN5O3Purity:97.56% - 99.9%Color and Shape:Off-White SolidMolecular weight:485.94Ref: TM-T21312
5mg35.00€10mg51.00€25mg86.00€50mg115.00€100mg144.00€200mg177.00€500mg300.00€1mL*10mM (DMSO)52.00€PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Formula:C45H41FN10O5Color and Shape:SolidMolecular weight:820.87Onartuzumab
CAS:Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Purity:97.3%Color and Shape:LiquidMolecular weight:146.99 kDaEmibetuzumab
CAS:Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Purity:SDS-PAGE:96.2%;SEC-HPLC:98.8%Color and Shape:LiquidMolecular weight:143.74 kDaCabozantinib
CAS:Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).Formula:C28H24FN3O5Purity:99.59% - 99.88%Color and Shape:SolidMolecular weight:501.51Crizotinib hydrochloride
CAS:Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Formula:C21H23Cl3FN5OPurity:98.73% - 98.87%Color and Shape:SolidMolecular weight:486.8Ref: TM-T8399
5mg37.00€10mg52.00€25mg82.00€50mg99.00€100mg138.00€200mg171.00€500mg227.00€1mL*10mM (DMSO)59.00€c-met-IN-1
CAS:c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.Formula:C35H37FN6O5Purity:98%Color and Shape:SolidMolecular weight:640.7Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Formula:C17H13BrN2Purity:97.67%Color and Shape:SolidMolecular weight:325.2Ref: TM-T25492
1mg38.00€2mg50.00€5mg85.00€10mg126.00€25mg245.00€50mg364.00€100mg507.00€200mg700.00€1mL*10mM (DMSO)96.00€Crizotinib
CAS:Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Formula:C21H22Cl2FN5OPurity:99% - 99.87%Color and Shape:SolidMolecular weight:450.34Narnatumab
CAS:Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.Color and Shape:LiquidSYN1143
CAS:SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Formula:C31H29FN4O5Purity:98.86%Color and Shape:SolidMolecular weight:556.58SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Formula:C28H30ClN5O4SPurity:98.62% - 99.44%Color and Shape:Orange PowderMolecular weight:568.09Ref: TM-T6154
1mg47.00€2mg59.00€5mg97.00€10mg150.00€25mg283.00€50mg465.00€100mg688.00€1mL*10mM (DMSO)150.00€SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Formula:C25H23FN8O2S2·HClPurity:97.95%Color and Shape:SolidMolecular weight:587Ref: TM-T5677
1mg38.00€5mg60.00€10mg90.00€25mg188.00€50mg279.00€100mg395.00€200mg567.00€1mL*10mM (DMSO)101.00€Glumetinib
CAS:Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).Formula:C21H17N9O2SPurity:99.79%Color and Shape:SolidMolecular weight:459.48
